- Home
- RSF vs BEAT Comparison
RSF vs BEAT Comparison
Compare RSF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | BEAT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 53.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RSF | BEAT |
|---|---|---|
| Price | $14.62 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 10.1K | ★ 575.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $0.54 |
| 52 Week High | $15.07 | $4.00 |
Technical Indicators
Market Signals| Indicator | RSF | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 47.18 |
| Support Level | $14.58 | $0.54 |
| Resistance Level | $14.73 | $0.81 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 47.59 | 72.37 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.